Spots Global Cancer Trial Database for avelumab
Every month we try and update this database with for avelumab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Avelumab for People With Recurrent Respiratory Papillomatosis | NCT02859454 | Recurrent Respi... Juvenile Laryng... Laryngeal Papil... Respiratory Pap... Human Papilloma... | Avelumab | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200) | NCT02155647 | Carcinoma, Merk... | Avelumab | 18 Years - | EMD Serono | |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies | NCT04068194 | Cholangiocarcin... Gallbladder Car... Stage III Gallb... Stage III Hilar... Stage III Intra... Stage IV Gallbl... Stage IV Hilar ... Stage IV Intrah... | Avelumab Biopsy Biospecimen Col... Computed Tomogr... Hypofractionate... Peposertib | 18 Years - | National Cancer Institute (NCI) | |
| Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer | NCT02875613 | Nasopharyngeal ... | Avelumab | 18 Years - | University of California, San Diego | |
| Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors | NCT03252938 | Solid Tumors Peritoneal Carc... | IMP321 Avelumab | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | NCT03035630 | Clear-cell Rena... RCC Kidney Cancer Clear-cell Kidn... | Avelumab Sunitinib | 18 Years - | Hoosier Cancer Research Network | |
| Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | NCT06225596 | Metastatic Urot... | BT8009 BT8009 BT8009 Pembrolizumab Gemcitabine + c... Avelumab | 18 Years - | BicycleTx Limited | |
| A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab | NCT03409458 | Non-Small Cell ... | PT-112 avelumab | 18 Years - | Promontory Therapeutics Inc. | |
| Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | NCT03787602 | Merkel Cell Car... | KRT-232 Avelumab | 18 Years - | Kartos Therapeutics, Inc. | |
| Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer | NCT03704467 | Ovarian Cancer | M6620 Avelumab Carboplatin | 18 Years - | EMD Serono | |
| Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS) | NCT03944252 | Squamous Cell A... | Avelumab Cetuximab | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Immunotherapy In Locally Advanced Rectal Cancer | NCT03854799 | Colon Rectal Ca... | Avelumab Capecitabine EXTERNAL---BEAM... | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer | NCT04561336 | Metastatic Colo... RAS Wild Type | Avelumab Cetuximab | 18 Years - | University of Campania "Luigi Vanvitelli" | |
| Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) | NCT02999087 | HNSCC | Cetuximab avelumab Cisplatin IMRT | 18 Years - 80 Years | Groupe Oncologie Radiotherapie Tete et Cou | |
| Immune Checkpoint Inhibitor In High Risk Oral Premalignant Lesions | NCT04504552 | Oral Premaligna... | Avelumab | 18 Years - | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | |
| QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy | NCT03853317 | Merkel Cell Car... | Avelumab N-803 haNK™ | 18 Years - | ImmunityBio, Inc. | |
| Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS Tumors | NCT05081180 | Central Nervous... | Avelumab Lenvatinib | 2 Years - 18 Years | EMD Serono | |
| An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION) | NCT04941768 | Carcinoma, Rena... | 18 Years - | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | ||
| Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL) | NCT04871529 | Bladder Carcino... Infiltrating Re... Stage II Bladde... | Therapeutic Con... Avelumab Gemcitabine Hyd... Carboplatin | 18 Years - | SWOG Cancer Research Network | |
| Montreal Immune-Related Adverse Events (MIRAE) Study | NCT05139706 | Cancer Immune System D... Inflammatory Re... Autoimmune Dise... | 18 Years - 100 Years | Sir Mortimer B. Davis - Jewish General Hospital | ||
| Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment | NCT03389126 | Carcinoma, Hepa... | Avelumab | 18 Years - | Seoul National University Hospital | |
| Study of Avelumab-M3814 Combinations | NCT03724890 | Oncology Solid Tumors | M3814 M3814 Avelumab Radiotherapy | 18 Years - | EMD Serono | |
| Avelumab (Bavencio) With IL-15 in Subjects With Clear-Cell Renal Carcinoma | NCT04150562 | Clear-Cell Rena... | rhIL-15 Avelumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study | NCT03891238 | Metastatic or L... | Avelumab | 18 Years - | Consorzio Oncotech | |
| Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study | NCT05092958 | Advanced Bladde... Advanced Renal ... Advanced Ureter... Advanced Urethr... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Stage III Bladd... Stage III Renal... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... | Avelumab Biospecimen Col... Bone Scan Cabozantinib S-... Computed Tomogr... Magnetic Resona... Quality-of-Life... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes | NCT03147404 | Neuroendocrine ... | Avelumab | 20 Years - | Samsung Medical Center | |
| QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. | NCT03387085 | Triple Negative... | Aldoxorubicin H... N-803 ETBX-011 ETBX-051 ETBX-061 GI-4000 GI-6207 GI-6301 haNK for Infusi... avelumab bevacizumab Capecitabine Cisplatin Cyclophosphamid... 5-Fluorouracil Leucovorin nab-Paclitaxel SBRT | 18 Years - | ImmunityBio, Inc. | |
| Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT02953561 | Acute Myeloid L... Recurrent Acute... Refractory Acut... | Avelumab Azacitidine Laboratory Biom... | 18 Years - | M.D. Anderson Cancer Center | |
| A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy | NCT03076554 | Thymoma Thymic Carcinom... | Avelumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy | NCT03826589 | Cervical Cancer | Avelumab Axitinib | 18 Years - | The University of Hong Kong | |
| AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients | NCT04513951 | Metastatic Colo... | 5Fluorouracil L-leucovorin Irinotecan Oxaliplatin Cetuximab Avelumab | 18 Years - 75 Years | Gruppo Oncologico del Nord-Ovest | |
| Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer | NCT04561336 | Metastatic Colo... RAS Wild Type | Avelumab Cetuximab | 18 Years - | University of Campania "Luigi Vanvitelli" | |
| Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors | NCT03252938 | Solid Tumors Peritoneal Carc... | IMP321 Avelumab | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma | NCT03966118 | Gastroesophagea... Adenocarcinoma ... | Avelumab Ramucirumab Paclitaxel | 18 Years - | Charite University, Berlin, Germany | |
| A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | NCT04215146 | Breast Cancer M... | Paclitaxel Pelareorep Avelumab | 18 Years - | Oncolytics Biotech | |
| Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART) | NCT05012865 | Renal Cell Carc... | avelumab axitinib | 20 Years - | Pfizer | |
| Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma | NCT04291885 | Merkel Cell Car... Merkel Cell Car... Merkel Cell Car... Merkel Cell Car... Neuroendocrine ... Carcinoma Neuro... | Avelumab Placebo | 18 Years - | Melanoma and Skin Cancer Trials Limited | |
| Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer | NCT03892642 | Bladder Cancer | Avelumab BCG | 18 Years - | University of Oklahoma | |
| Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors | NCT03252938 | Solid Tumors Peritoneal Carc... | IMP321 Avelumab | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy | NCT03352934 | Cancer | Avelumab | 18 Years - | Johannes Gutenberg University Mainz | |
| VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | NCT03750071 | Recurrent Gliob... | VXM01 Avelumab | 18 Years - | Vaximm GmbH | |
| QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | NCT03574649 | Non Small Cell ... | Nab-paclitaxel Cisplatin 5Fluorouracil Cyclophosphamid... ETBX-011 ETBX-051 ETBX-061 GI-4000 GI-6301 Aldoxorubicin Avelumab ALT-803 haNK Docetaxel carboplatin | 18 Years - | ImmunityBio, Inc. | |
| Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] | NCT03439501 | Lymphoma, Extra... | avelumab | 20 Years - | Samsung Medical Center | |
| Targeting the Tumor Microenvironment in R/M SCCHN | NCT03844763 | Head and Neck C... | Avelumab CTX RT | 18 Years - | Gruppo Oncologico del Nord-Ovest | |
| Avelumab With Valproic Acid in Virus-associated Cancer | NCT03357757 | Cancer That is ... p16 Positive SC... Squamous Cell C... p16 Positive Sq... p16 Positive Sq... p16 Positive Sq... EBER Positive N... EBER Positive H... | Valproic Acid Avelumab | 18 Years - | AHS Cancer Control Alberta | |
| Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers | NCT03260023 | HPV-Related Car... HPV-Related Cer... HPV-Related Ana... HPV-Related Pen... HPV-Related Vul... | TG4001 Avelumab | 18 Years - | Transgene | |
| Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients | NCT03152565 | Colorectal Carc... | Avelumab | 18 Years - | Grupo Espanol Multidisciplinario del Cancer Digestivo | |
| Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer | NCT03617913 | Bladder Carcino... Stage II Bladde... Stage II Renal ... Stage II Ureter... Stage II Urethr... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Urethral Urothe... | Avelumab Cisplatin Fluorouracil Mitomycin Quality-of-Life... Radiation Thera... | 18 Years - | Mayo Clinic | |
| EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer | NCT03494322 | Head and Neck C... Squamous Cell C... | Avelumab Cetuximab | 18 Years - | University College, London | |
| Avelumab in First-line NSCLC (JAVELIN Lung 100) | NCT02576574 | First Line Non-... | Avelumab Pemetrexed Paclitaxel Gemcitabine Gemcitabine Carboplatin Cisplatin Carboplatin Avelumab Weekly | 18 Years - | EMD Serono | |
| A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy | NCT03270176 | Carcinoma, Non-... Neoplasms | Debio 1143 Avelumab | 18 Years - | Debiopharm International SA | |
| Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma | NCT02584829 | Merkel Cell Pol... Stage IV Merkel... | Avelumab Laboratory Biom... MCPyV TAg-speci... Radiation Thera... Recombinant Int... | 18 Years - | Fred Hutchinson Cancer Center | |
| QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy | NCT03169764 | Head and Neck S... | Avelumab Bevacizumab Capecitabine Cetuximab Cisplatin cyclophosphamid... 5-Fluorouracil ... fulvestrant leucovorin nab-paclitaxel nivolumab Lovaza Stereotactic Bo... ALT-803 ETBX-011 ETBX-021 ETBX-051 ETBX-061 GI-4000 GI-6207 GI-6301 haNK | 18 Years - | ImmunityBio, Inc. | |
| M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas | NCT03451773 | Cancer of Pancr... Pancreas Cancer Pancreatic Aden... Pancreatic Canc... Pancreatic Neop... | M7824 Gemcitabine | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma | NCT03774901 | Penile Cancer Penile Neoplasm... Penile Squamous... | Avelumab | 18 Years - | Centre Hospitalier Universitaire de Besancon | |
| JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study | NCT06412848 | Urothelial Carc... | Avelumab | 18 Years - | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | |
| Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3) | NCT05289856 | Cancer | combination of ... | 18 Years - | Johannes Gutenberg University Mainz | |
| Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer | NCT05600127 | Urothelial Carc... | Avelumab | 18 Years - | Erasmus Medical Center | |
| Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing | NCT05059522 | Advanced Malign... NSCLC Ovarian Cancer Urothelial Canc... Solid Tumors | Avelumab Lorlatanib Talazoparib Pemetrexed Axitinib CMP 001 Utomilumab PF04518600 | 18 Years - | Pfizer | |
| The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma | NCT03800953 | Esophageal Tumo... Metastatic Esop... | Avelumab | 20 Years - | National Taiwan University Hospital | |
| AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma | NCT03893903 | Malignant Gliom... | IDH1R132H pepti... Avelumab | 18 Years - | German Cancer Research Center | |
| Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer | NCT03186326 | Metastatic Colo... MSI | FOLFOX regimen FOLFIRI Protoco... Avelumab Panitumumab Cetuximab Bevacizumab Aflibercept | 18 Years - | Federation Francophone de Cancerologie Digestive | |
| The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | NCT03414658 | Breast Cancer | Vinorelbine Trastuzumab Avelumab Utomilumab | 18 Years - | Dana-Farber Cancer Institute | |
| A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer | NCT03258398 | Microsatellite ... | eFT508 Avelumab | 18 Years - | Effector Therapeutics | |
| Avelumab and Methotrexate in in Low-risk Gestational Trophoblastic Neoplasias as First Line Treatment | NCT04396223 | Gestational Tro... | Avelumab Inject... Methotrexate 1 ... | 18 Years - | Hospices Civils de Lyon | |
| A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200) | NCT02580058 | Ovarian Cancer | avelumab PLD | 18 Years - | Pfizer | |
| QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy | NCT03387098 | Pancreatic Canc... | Aldoxorubicin H... ALT-803 ETBX-011 GI-4000 haNK for infusi... avelumab bevacizumab Capecitabine Cyclophosphamid... Fluorouracil Leucovorin nab-Paclitaxel lovaza Oxaliplatin SBRT | 18 Years - | ImmunityBio, Inc. | |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | NCT03169738 | Non-small Cell ... | avelumab Bevacizumab Capecitabine Cisplatin cyclophosphamid... 5-Fluorouracil ... fulvestrant leucovorin nab paclitaxel nivolumab Lovaza Oxaliplatin Stereotactic Bo... ALT-803 ETBX-011 ETBX-021 ETBX-051 ETBX-061 GI-4000 GI-6207 GI-6301 haNK | 18 Years - | ImmunityBio, Inc. | |
| QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy | NCT03175666 | Triple Negative... | avelumab bevacizumab capecitabine cisplatin cyclophosphamid... 5-Fluorouracil Leucovorin nab-paclitaxel Lovaza Stereotactic Bo... ALT-803 ETBX-011 ETBX-051 ETBX-061 GI-4000 GI-6207 GI-6301 haNK | 18 Years - | ImmunityBio, Inc. | |
| Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer | NCT03573648 | Breast Cancer | Avelumab Endocrine thera... Palbociclib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] | NCT03439501 | Lymphoma, Extra... | avelumab | 20 Years - | Samsung Medical Center | |
| Trial of INI-4001 in Patients With Advanced Solid Tumours | NCT06302426 | Advanced Solid ... | INI-4001 Nivolumab Pembrolizumab Cemiplimab Avelumab Atezolizumab Durvalumab | 18 Years - | Inimmune Corporation | |
| SOGUG-AVELUMAB_RWD | NCT05700344 | Metastatic Urot... | Avelumab | 18 Years - 120 Years | Spanish Oncology Genito-Urinary Group | |
| CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy | NCT05291156 | Metastatic Colo... | Cetuximab Avelumab | 18 Years - | University of Campania "Luigi Vanvitelli" | |
| A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) | NCT03289533 | Carcinoma, Hepa... | Avelumab (MSB00... Axitinib (AG-01... | 20 Years - | Pfizer | |
| RITUXIMAB + IMMUNOTHERAPY IN FOLLICULAR LYMPHOMA | NCT03636503 | Follicular Lymp... | Rituximab Utomilumab Avelumab PF04518600 | 18 Years - | Dana-Farber Cancer Institute | |
| QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors | NCT03169738 | Non-small Cell ... | avelumab Bevacizumab Capecitabine Cisplatin cyclophosphamid... 5-Fluorouracil ... fulvestrant leucovorin nab paclitaxel nivolumab Lovaza Oxaliplatin Stereotactic Bo... ALT-803 ETBX-011 ETBX-021 ETBX-051 ETBX-061 GI-4000 GI-6207 GI-6301 haNK | 18 Years - | ImmunityBio, Inc. | |
| A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100) | NCT03289533 | Carcinoma, Hepa... | Avelumab (MSB00... Axitinib (AG-01... | 20 Years - | Pfizer | |
| Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | NCT03498378 | Head and Neck S... | Avelumab Palbociclib Cetuximab | 18 Years - | University of California, San Diego | |
| Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma | NCT03774901 | Penile Cancer Penile Neoplasm... Penile Squamous... | Avelumab | 18 Years - | Centre Hospitalier Universitaire de Besancon |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
